JP2024534178A5 - - Google Patents

Info

Publication number
JP2024534178A5
JP2024534178A5 JP2024513275A JP2024513275A JP2024534178A5 JP 2024534178 A5 JP2024534178 A5 JP 2024534178A5 JP 2024513275 A JP2024513275 A JP 2024513275A JP 2024513275 A JP2024513275 A JP 2024513275A JP 2024534178 A5 JP2024534178 A5 JP 2024534178A5
Authority
JP
Japan
Prior art keywords
vector
nucleic acid
acid sequence
fusion protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534178A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/075645 external-priority patent/WO2023034783A1/en
Publication of JP2024534178A publication Critical patent/JP2024534178A/ja
Publication of JP2024534178A5 publication Critical patent/JP2024534178A5/ja
Pending legal-status Critical Current

Links

JP2024513275A 2021-08-31 2022-08-30 結核ワクチン Pending JP2024534178A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163239278P 2021-08-31 2021-08-31
US63/239,278 2021-08-31
US202263392778P 2022-07-27 2022-07-27
US63/392,778 2022-07-27
PCT/US2022/075645 WO2023034783A1 (en) 2021-08-31 2022-08-30 Tuberculosis vaccines

Publications (2)

Publication Number Publication Date
JP2024534178A JP2024534178A (ja) 2024-09-18
JP2024534178A5 true JP2024534178A5 (enExample) 2025-08-25

Family

ID=83447900

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513275A Pending JP2024534178A (ja) 2021-08-31 2022-08-30 結核ワクチン

Country Status (12)

Country Link
US (1) US20240350607A1 (enExample)
EP (1) EP4396208A1 (enExample)
JP (1) JP2024534178A (enExample)
KR (1) KR20240049802A (enExample)
AU (1) AU2022339918A1 (enExample)
CA (1) CA3226978A1 (enExample)
CL (1) CL2024000600A1 (enExample)
CO (1) CO2024001517A2 (enExample)
IL (1) IL310667A (enExample)
MX (1) MX2024001964A (enExample)
TW (1) TW202328167A (enExample)
WO (1) WO2023034783A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024188336A1 (zh) * 2023-03-15 2024-09-19 康希诺生物股份公司 一种肺结核疫苗及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
EP2315773B1 (en) * 2008-07-25 2016-08-24 GlaxoSmithKline Biologicals S.A. Polypeptides, polynucleotides and compositions for use in the treatment of latent tubeculosis
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
PT3351636T (pt) 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
LT2964769T (lt) 2013-03-05 2018-12-10 Oregon Health & Science University Citomegalo viruso vektoriai, leidžiantys kontroliuoti ląstelių nukreipimą į taikinį
EA201791806A1 (ru) 2015-02-10 2017-12-29 Орегон Хелс Энд Сайенс Юниверсити Способы и композиции, полезные при генерировании неканонических cd8+ т-клеточных ответов
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
US10688164B2 (en) 2015-11-20 2020-06-23 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
AU2017280065B2 (en) * 2016-06-22 2021-07-01 International Aids Vaccine Initiative, Inc. Recombinant cytomegalovirus vectors as vaccines for tuberculosis
WO2018075591A1 (en) 2016-10-18 2018-04-26 Oregon Health & Science University Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules

Similar Documents

Publication Publication Date Title
Winter et al. The structure of the gene encoding the nucleoprotein of human influenza virus A/PR/8/34
CN110862435B (zh) 非洲猪瘟ctl表位多肽及其应用
CN111533809A (zh) 针对新型冠状病毒的亚单位疫苗及应用
Ren et al. Design and evaluation of a multi-epitope assembly peptide vaccine against Acinetobacter baumannii infection in mice
Stohwasser et al. Molecular characterization of the RNA S segment of nephropathia epidemica virus strain Hällnäs B1
KR20120083899A (ko) 마이코박테리아 백신들
US20230242627A1 (en) Composition and method for activating latent human immunodeficiency virus (hiv)
JP2009520463A5 (enExample)
JP2009529576A5 (enExample)
CN115246874A (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
WO2023138334A1 (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
KR20210133225A (ko) 부착된 이종 분자를 car-세포의 비천연 nkg2d 수용체에 선택적으로 전달하는 변형된 비천연 nkg2d 리간드
CN115521942B (zh) 一种bvdv表位基因疫苗的构建方法及其应用
JP2023522154A5 (enExample)
JP2024537250A5 (enExample)
WO2006085583A1 (ja) 細胞透過性ペプチド
JP2010535504A5 (enExample)
CN113249408A (zh) 一种靶向激活体液免疫和细胞免疫的核酸疫苗载体构建及应用
WO2023138333A1 (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
CA2327353A1 (en) Structural proteins of fish pancreatic disease virus and uses thereof
JP2016513963A (ja) 免疫調節
CN113365655A (zh) 包含糖基化ag85a蛋白的用于预防结核病的疫苗组合物及其制备方法
KR101570453B1 (ko) 돼지 유행성 설사 바이러스의 재조합 스파이크 1 단백질을 발현하는 재조합 세포
JP2024523329A5 (enExample)
CA2378437C (en) Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines